| Similar Articles |
|---|
 |
Financial Planning
February 1, 2005
Neil A. O'Hara |
The Harvest to Come Pharmaceutical stocks may be down, but they're hardly out. For planners and clients who can tolerate the risk of concentration, a selective allocation to the healthcare industry today may represent the ability to buy growth at a value price.   |
Investment Advisor
April 2010
Vaughan Scully |
The ETF Advisor: Prospects for Healthcare ETFs Better Than Those for Reform There are about two dozen exchange traded funds that offer a wide variety of exposures to the healthcare sector, including broad-based, global, and leveraged ETFs, as well as those targeting individual industries. |
Financial Planning
April 1, 2007
Donald Jay Korn |
Healthcare Housing The REIT Rx: Investing in healthcare-related real estate could be a prescription for profitability. |
The Motley Fool
May 20, 2011
Arlene Weintrab. |
Miller Tabak Fund Manager Says Investors Are Ignoring the Upsides in Healthcare This manager says investors in 2013 are going to look back and wish they had invested more in healthcare funds today. |
Registered Rep.
March 1, 2005
David A. Twibell |
What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in. |
Financial Planning
April 1, 2008
Elizabeth O'Brien |
Prognosis: Mixed Healthcare stocks do tend to outperform in a weak economy. But lackluster drug pipelines and other pressures mean that the traditional definition of this industry as a refuge may not be as true as in the past. |
Financial Planning
October 1, 2005
Ilana Polyak |
Fund Manager Profile: Medicine Man Parsing out the hype from the substance has been a cornerstone of Sam Isaly's approach. As founder of OrbiMed Advisors and subadviser to the $2.5 billion Eaton Vance World Health Sciences fund, which he's run since 1989, Isaly has had a comfortable perch from which to watch drug stocks. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
Financial Planning
January 1, 2007
Donald Jay Korn |
Outlook 2007: A Year for the Big Guys? An economic slowdown is likely to spur a flight to quality, as investors shift their focus to the most powerful domestic large caps. |
Financial Planning
January 1, 2005
Donald Jay Korn |
Fancy Footwork Just as the economy is expected to muddle through this year, consensus forecasts indicate parallel plodding in the financial markets, with unspectacular returns for stocks and bonds. Financial planners seeking to thrive in 2005 may need to develop new tactics. |
Financial Planning
January 1, 2005
Donald Jay Korn |
Another Ride Are advisers and their clients really ready to get on the technology fund roller coaster again? |
Registered Rep.
September 26, 2011
Stan Luxenberg |
Despite Ill Winds, Health Stocks Look Healthy Health stock valuations look compelling, and many companies should report solid earnings growth. |
Financial Planning
January 1, 2006
Bob Hirschfeld |
The Long and Short of It ICON Long/Short Fund Manager J.C. Waller isolates sectors and industries that are underpriced relative to fair market value but show relative strength compared with the broad market. |
Financial Planning
April 1, 2005
Kristen French |
5 Investors to Follow A look at five fund managers with a winning view of the world. #1: The Leisure-Time Investor... #2: The International investor... #3: The Preservationist... |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
Financial Planning
January 1, 2006
Donald Jay Korn |
Outlook 2006 An informal survey of investment strategists found an upbeat economic outlook for 2006: Panic and Euphoria... Has Technology's Time Come?... Bond Parsing... Overseas Picture... Fiscal Forecast... |
The Motley Fool
March 15, 2007
Brian Lawler |
It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers. |
BusinessWeek
September 12, 2005
Lewis Braham |
Building A Focused Fund Of Your Own Portfolios of under 50 stocks have outrun the market with less risk. Here's how they do it. |
BusinessWeek
January 24, 2005 |
A Steady Hand Beats the Bears Lou Holland's fund has outperformed its battered large-cap peers by sticking to a growth-at-a-reasonable-price strategy. |
The Motley Fool
October 11, 2004
Roger Nusbaum |
Pfizer: Prognosis Critical This American icon seems destined to lag for the forseeable future. |
Financial Planning
June 1, 2005
Russell Wild |
Style War Some financial advisers argue that there's more than one way to slice a portfolio. |
Financial Advisor
October 2004
Alan Lavine |
Pondering The Fate Of Mid-Cap Stock Funds Is the market rotating away from this once-hot sector? |
Financial Planning
March 1, 2006
Craig L. Israelsen |
Hidden Measures How did U.S. stocks perform versus U.S. equity mutual funds last year? The market-cap bias in measuring stock returns tends to obscure the true return picture. |
Pharmaceutical Executive
February 1, 2009
Jill Wechsler |
Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths. |
Financial Planning
March 1, 2005
Israelsen & Clement |
Of Stocks and Funds Financial advisers need to explain to their clients that diversification can be a double-edged sword; protection against loss can sometimes insulate against return. Here's a performance comparison of individual stocks vs. equity funds in 2004. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
BusinessWeek
October 10, 2005
Lewis Braham |
The Growing Interest In Growth Stocks Lately growth stocks are outrunning value funds. |
Financial Planning
February 1, 2006
Bob Hirschfeld |
Ninth-Inning Save Although indexes were lackluster, large caps rallied toward the end of the year. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
February 28, 2011
David Williamson |
Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio |
The Motley Fool
February 22, 2005
Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
Pharmaceutical Executive
July 30, 2007
Peter Pitts |
Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy. |
Financial Advisor
January 2006
Marla Brill |
Bold Bets Fund managers who run concentrated portfolios offer a refreshing departure from the increasingly popular practice of far-reaching, benchmark-centric investing. |
Financial Advisor
June 2005
Marla Brill |
Fishing For Fallen Angels Putnam's David King shops for bargains among tarnished growth stocks. |
The Motley Fool
July 31, 2009
Brian Orelli |
Can Emerging Markets Save Pharma? Probably not until after they emerge. |
Financial Planning
January 1, 2005
Bernard R. Horn |
Global Goodies It's not risky to invest overseas--in fact, it's riskier not to. Exchange rates and political and economic risks can mitigate returns, but experienced global equity managers know how to navigate foreign markets by making solid stock picks. |
Investment Advisor
April 2006
Kathleen M. McBride |
Anything but Middling Munder's Mid-Cap Core Growth Fund's Tony Dong has prospered by finding growth wherever. |
BusinessWeek
January 24, 2005 |
Searching for "Emerging Quality" Goldman Sachs Mid-Cap Value's Eileen Rominger focuses on cheaply priced stocks with potential for positive change. |
The Motley Fool
September 14, 2004
Tim Beyers |
Finding Profitable Funds In this Q & A, Champion Funds chief analyst Shannon Zimmerman covers how he looks for funds, why sector funds might not be a good bet, and whether or not the fund scandal is really winding down. |
The Motley Fool
January 20, 2006
Doug Short |
Competing With the S&P 500 If you want to increase your chance of beating the S&P 500 year after year, one good way is to broaden your investment choices to include a generous mix of smaller caps and international equities. Mutual funds and ETFs offer an easy means to get that degree of breadth. |
Registered Rep.
March 1, 2003
Stan Luxenburg |
Going to Extremes Used as the "explore" part of a "core and explore" strategy, focus can indeed help produce alpha (outperformance). |
Investment Advisor
January 2006
Kathleen M. McBride |
Many Happy Returns Stratton Growth Fund has displayed a disciplined approach to all-cap value investing that has outperformed for decades. |
Pharmaceutical Executive
February 1, 2011
William Looney |
Tracking the US Market: A Statistical Self-Portrait What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light |
Financial Advisor
October 2005
Alan Lavine |
Tech Stocks: Down So Long That They Look Up After trailing the broad market over the past several years, some analysts expect tech stocks to rally. Their price-to-earnings multiples are low in relation to future earnings. |
Financial Planning
April 1, 2006
Len Reinhart |
The Equity Puzzle Stocks are a critical component of lifetime investment plans, but clients need more than cookie-cutter allocations and market-mirror index funds. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
October 8, 2004
Whitney Tilson |
Blue-Chip Bargains? Sifting through beaten-down stocks may yield some good investments. But be careful, most of these stocks are that way for a reason. |
Pharmaceutical Executive
February 1, 2011
Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country |
Financial Advisor
March 2004
Marla Brill |
Filling The Tax-Favored Dividend Void Investors seem to covet higher dividends and lower taxes. Forty-three percent of respondents to a recent survey of 600 individuals conducted by American Century Investments said they are more likely to buy stocks that pay dividends qualifying for the new tax rate. |
Investment Advisor
August 2005
Angelina Dance |
S&P Mutual Fund Sector Focus: Small-Cap Growth Still Packing a Punch Growth investing, particularly in the small-cap sector, has traditionally been considered a high-risk approach, yet in the past several years has proven to be rewarding. |
